HomeCompareYMTX vs QYLD

YMTX vs QYLD: Dividend Comparison 2026

YMTX yields 105.82% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YMTX wins by $4.90M in total portfolio value
10 years
YMTX
YMTX
● Live price
105.82%
Share price
$1.89
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.93M
Annual income
$1,723,843.10
Full YMTX calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — YMTX vs QYLD

📍 YMTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYMTXQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YMTX + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YMTX pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YMTX
Annual income on $10K today (after 15% tax)
$8,994.71/yr
After 10yr DRIP, annual income (after tax)
$1,465,266.64/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, YMTX beats the other by $1,460,456.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YMTX + QYLD for your $10,000?

YMTX: 50%QYLD: 50%
100% QYLD50/50100% YMTX
Portfolio after 10yr
$2.48M
Annual income
$864,751.21/yr
Blended yield
34.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YMTX right now

YMTX
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-21.9
Piotroski
3/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YMTX buys
0
QYLD buys
0
No recent congressional trades found for YMTX or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYMTXQYLD
Forward yield105.82%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.93M$25.4K
Annual income after 10y$1,723,843.10$5,659.31
Total dividends collected$4.43M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: YMTX vs QYLD ($10,000, DRIP)

YearYMTX PortfolioYMTX Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$21,282$10,582.01$10,352$1,192.36+$10.9KYMTX
2$43,819$21,047.33$10,830$1,347.57+$33.0KYMTX
3$87,387$40,500.83$11,460$1,539.07+$75.9KYMTX
4$168,990$75,485.74$12,275$1,777.84+$156.7KYMTX
5$317,245$136,425.12$13,323$2,078.95+$303.9KYMTX
6$578,807$239,355.52$14,667$2,463.34+$564.1KYMTX
7$1,027,455$408,130.85$16,396$2,960.57+$1.01MYMTX
8$1,776,463$677,086.81$18,631$3,612.97+$1.76MYMTX
9$2,994,908$1,094,092.83$21,548$4,482.15+$2.97MYMTX
10$4,928,395$1,723,843.10$25,398$5,659.31+$4.90MYMTX

YMTX vs QYLD: Complete Analysis 2026

YMTXStock

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Full YMTX Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this YMTX vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YMTX vs SCHDYMTX vs JEPIYMTX vs OYMTX vs KOYMTX vs MAINYMTX vs XYLDYMTX vs JEPQYMTX vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.